Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study: BRIGHTEN: double-blind randomized study of ipragliflozin to show its efficacy as monotherapy in T2DM patients

Diabetology International

Volumn 6, Issue 1, 2015, Pages 8-18

  Kashiwagi, Atsunori ^a   Kazuta, Kenichi ^b   Takinami, Yuusuke ^b   Yoshida, Satoshi ^b   Utsuno, Atsushi ^b   Nagase, Itsuro ^b  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Diabetes mellitus; Hypoglycemia; Ipragliflozin; Monotherapy; SGLT2

Indexed keywords

ANTIDIABETIC AGENT; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; METFORMIN; PIOGLITAZONE; PLACEBO;

ADULT; ARTICLE; BACKACHE; BACTERIAL INFECTION; BALANOPOSTHITIS; BODY WEIGHT; CHRONOTHERAPY; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DIABETIC PATIENT; DIET RESTRICTION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; FEMALE; GENITAL PRURITUS; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TINEA PEDIS; TREATMENT DURATION; URINARY TRACT INFECTION; WAIST CIRCUMFERENCE;

EID: 84924960288     PISSN: 21901678     EISSN: 21901686     Source Type: Journal    
DOI: 10.1007/s13340-014-0164-0     Document Type: Article

References (28)

1. World Health Organization. Diabetes. Fact Sheet 312. Geneva: World Health Organization; 2011.
2. Ministry of Health, Labour, and Welfare, Japan. Results of the National Health and Nutrition Survey Japan, 2007. Tokyo: Ministry of Health, Labour, and Welfare, Japan; 2007.
3. Neumiller JJ, White JR Jr, Campbell RK. Sodium–glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70:377–85.
4. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Investig. 1994;93:397–404.
5. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:423–36.
6. Kadokura T, Saito M, Utsuno A, Kazuta K, Yoshida S, Kawasaki S, Nagase I, Kageyama S. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int. 2011;2:172–82.
7. Veltkamp SA, Kadokura T, Krauwinkel WJJ, Smulders RA. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011;31:839–51.
8. Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13:1219–27.
9. Kashiwagi A, Kazuta K, Yoshida S, Nagase I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013. doi:10.1111/jdi.12156.
10. Fonseca VA, Ferrannini E, Wilding JPH, Wilpshaar W, Dhanjal P, Ball G, Klasen S. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complicat. 2013;27:268–73.
11. Wilding JPH, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15:403–9.
12. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10.
13. Tajima N, Kadowaki T, Odawara M, Nishii M, Taniguchi T, Ferreira JCMA. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int. 2011;2:32–44.
14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
15. Igel LI, Powell AG, Apovian CM, Aronne LJ. Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. Curr Atheroscler Rep. 2012;14:60–9.
16. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734–43.
17. Bailey CJ. The challenge of managing coexistent type 2 diabetes and obesity. BMJ. 2011;342:d1996.
18. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
19. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
20. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;9(Suppl 4):326S–34S.
21. Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31.
22. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610–30.
23. Rossetti L, Hawkins M, Chen W, Gindi J, Barzilai N. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin Investig. 1995;96:132–40.
24. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28:1173–8.
25. 1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473–8.
26. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium–glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–7.
27. Ljunggren Ö, Bolinder J, Johansson L, Wilding JPH, Langkilde AM, Sjöstrom CD, Sugg J, Parikh S. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990–9.
28. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W. Dose-ranging effects of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–8.